VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

ESOC 2022 | Key Updates from ESOC 2022

Aristeidis Katsanos, MD, McMaster University, Hamilton, Ontario, Canada, comments on practice changing data presented at the European Stroke Organisation Conference (ESOC) 2022, highlighting findings of tenecteplase’s non-inferiority compared to alteplase and the benefits of endovascular treatment in basilar artery occlusion (BAO) as major triumphs. Several studies presented at ESOC directly compared tenecteplase to alteplase. Data suggested tenecteplase was as efficacious as alteplase (AcT trial; NCT03889249), easier to use, and feasible in a mobile stroke unit (MSU) setting. The ATTENTION trial was another highlight, demonstrating a significant difference in favorable outcomes in the thrombectomy group compared to best medical management (46% vs. 24%), in patients with acute ischemic stroke with BAO. This interview took place at European Stroke Organisation Conference 2022 in Lyon, France.